These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 28966198)

  • 21. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections.
    Veve MP; Wagner JL; Kenney RM; Grunwald JL; Davis SL
    Int J Antimicrob Agents; 2016 Jul; 48(1):56-60. PubMed ID: 27234673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
    Carmeli Y; Armstrong J; Laud PJ; Newell P; Stone G; Wardman A; Gasink LB
    Lancet Infect Dis; 2016 Jun; 16(6):661-673. PubMed ID: 27107460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk factors for urinary tract infection caused by Enterobacteriaceae with extended-spectrum beta-lactamase resistance in patients admitted to internal medicine departments.
    Vardi M; Kochavi T; Denekamp Y; Bitterman H
    Isr Med Assoc J; 2012 Feb; 14(2):115-8. PubMed ID: 22693794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Which proportion of extended-spectrum beta-lactamase producing strains could be treated by non-carbapenem beta-lactams?
    Canoui E; Tankovic J; Bige N; Alves M; Offenstadt G
    Med Mal Infect; 2014 May; 44(5):235-7. PubMed ID: 24780641
    [No Abstract]   [Full Text] [Related]  

  • 25. "Double carbapenem" and oral fosfomycin for the treatment of complicated urinary tract infections caused by bla
    Rosa R; Rudin SD; Rojas LJ; Hujer AM; Perez-Cardona A; Perez F; Bonomo RA; Martinez O; Abbo LM; Camargo JF
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29064133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carbapenem-sparing beta-lactam/beta-lactamase inhibitors versus carbapenems for bloodstream infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a systematic review and meta-analysis.
    Zhang H; Xu J; Xiao Q; Wang Y; Wang J; Zhu M; Cai Y
    Int J Infect Dis; 2023 Mar; 128():194-204. PubMed ID: 36621752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cefoxitin: An alternative to carbapenems in urinary tract infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Mambie A; Vuotto F; Poitrenaud D; Weyrich P; Cannesson O; Dessein R; Faure K; Guery B; Galpérine T
    Med Mal Infect; 2016 Jun; 46(4):215-9. PubMed ID: 27210283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of non-carbapenem antibiotics for pediatric patients with first febrile urinary tract infection due to extended-spectrum beta-lactamase-producing Escherichia coli.
    Abe Y; Inan-Erdogan I; Fukuchi K; Wakabayashi H; Ogawa Y; Hibino S; Sakurai S; Matsuhashi K; Watanabe Y; Hashimoto K; Ugajin K; Itabashi K
    J Infect Chemother; 2017 Aug; 23(8):517-522. PubMed ID: 28528936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management.
    Kaye KS; Pogue JM
    Pharmacotherapy; 2015 Oct; 35(10):949-62. PubMed ID: 26497481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.
    Kaniga K; Flamm R; Tong SY; Lee M; Friedland I; Redman R
    Antimicrob Agents Chemother; 2010 May; 54(5):2119-24. PubMed ID: 20211892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae.
    Gutiérrez-Gutiérrez B; Pérez-Galera S; Salamanca E; de Cueto M; Calbo E; Almirante B; Viale P; Oliver A; Pintado V; Gasch O; Martínez-Martínez L; Pitout J; Akova M; Peña C; Molina J; Hernández A; Venditti M; Prim N; Origüen J; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Giamarellou H; Almela M; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Mora-Rillo M; Natera C; Souli M; Bonomo RA; Carmeli Y; Paterson DL; Pascual A; Rodríguez-Baño J
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4159-69. PubMed ID: 27139473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extended-spectrum beta-lactamase-producing organisms.
    Falagas ME; Karageorgopoulos DE
    J Hosp Infect; 2009 Dec; 73(4):345-54. PubMed ID: 19596491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evolution of antibiotic treatments for healthcare-associated infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae in France.
    Lecuru M; Daniau C; Alfandari S; Dumartin C; Bajolet O; Blanchard H; Simon L; Anne-Berger-Carbonne ; Colomb-Cotinat M
    Infect Dis Now; 2022 Oct; 52(7):396-402. PubMed ID: 36041699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biliary diseases as main causes of pyogenic liver abscess caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Shi SH; Feng XN; Lai MC; Kong HS; Zheng SS
    Liver Int; 2017 May; 37(5):727-734. PubMed ID: 27718321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Doi A; Shimada T; Harada S; Iwata K; Kamiya T
    Int J Infect Dis; 2013 Mar; 17(3):e159-63. PubMed ID: 23140947
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the relative efficacy of β-lactam/β-lactamase inhibitors and carbapenems in the treatment of complicated urinary tract infections caused by ceftriaxone-non-susceptible Enterobacterales: a multicentre retrospective observational cohort study.
    Chen L; Hua J; Hong SJ; Yuan CY; Jing RC; Luo XY; Xue HW; Yue Y; He XP
    J Antimicrob Chemother; 2023 Mar; 78(3):710-718. PubMed ID: 36691860
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Study of family physicians' practices in case of urinary tract infections caused by enterobacteriaceae secreting extended-spectrum-beta-lactamase.
    Miclot C; Antoniotti G; Forestier E
    Med Mal Infect; 2015 Mar; 45(3):78-83. PubMed ID: 25676475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
    Ofer-Friedman H; Shefler C; Sharma S; Tirosh A; Tal-Jasper R; Kandipalli D; Sharma S; Bathina P; Kaplansky T; Maskit M; Azouri T; Lazarovitch T; Zaidenstein R; Kaye KS; Marchaim D
    Infect Control Hosp Epidemiol; 2015 Aug; 36(8):981-5. PubMed ID: 25990361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development and validation of a bedside instrument to predict carbapenem resistance among gram-negative pathogens in complicated urinary tract infections.
    Zilberberg MD; Nathanson BH; Sulham K; Fan W; Shorr AF
    Infect Control Hosp Epidemiol; 2018 Sep; 39(9):1112-1114. PubMed ID: 30060775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nosocomial pneumonia caused by carbapenem-resistant Raoultella planticola: a case report and literature review.
    Xu M; Xie W; Fu Y; Zhou H; Zhou J
    Infection; 2015 Apr; 43(2):245-8. PubMed ID: 25595510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.